Imatinib Mesylate Api

Imatinib Mesylate API (CAS No. 220127-57-1) is a premium Active Pharmaceutical Ingredient used in the formulation of targeted cancer therapies. Classified as a tyrosine kinase inhibitor (TKI), it works by blocking abnormal proteins that drive cancer cell growth. Imatinib Mesylate is widely used in the treatment of: Chronic Myeloid Leukemia (CML) Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL) Gastrointestinal Stromal Tumors (GISTs) Myelodysplastic/Myeloproliferative diseases (MDS/MPD) Aggressive systemic mastocytosis (ASM) Dermatofibrosarcoma protuberans (DFSP) Other rare hematologic and solid tumor conditions Its targeted mechanism of action makes it a critical component in modern oncology therapy. Specifications & Details: Product Name: Imatinib Mesylate Synonyms: Imatinib mesilate Product Code: ATM125IMAT Grade: EP / In‑House Molecular Formula: C30H35N7O4S Molecular Weight: 589.7 g/mol CAS Number: 220127‑57‑1 COA & MSDS: Available on request Packaging: HDPE drums with double liner bags Storage: Store in air‑tight containers, protected from light and moisture Key Features: WHO‑GMP certified manufacturing Export‑quality oncology API High purity and consistent batch‑wise quality Complies with international pharmacopeial standards Applications: Used in pharmaceutical formulations for targeted cancer treatment, especially for leukemias, GISTs, and other tyrosine kinase‑driven malignant disorders. About the Company GST Registration Date: 2020 Legal Status of Firm: Proprietorship Number of Employees: 11 To 25 People Annual Turnover: 40 L - 1.5 Cr